Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 15Breast Neoplasms 10Neoplasms 2Advanced Breast Cancer 2Recurrence 1Prostate Adenocarcinoma 1Primary Ovarian Insufficiency 1Myofibroma 1Hormone-sensitive Metastatic Breast Cancer 1Breast Neoplasms, Male 1Advanced Prostate Cancer 1

Interventions

Letrozole 1Goserelin 1Erlotinib Hydrochloride 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hormone-sensitive Metastatic Breast Cancer × Goserelin × Clear all
NCT01205685 2012-09-11

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
11 enrolled 9 charts
Breast

Hormone-sensitive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡